A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.

Trial Profile

A Phase I, Open Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic and Clinical Activity of PF-06863135, a BCMA-CD3 Bispecific Antibody, in Patients With Relapsed/Refractory Advanced Multiple Myeloma.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2018

At a glance

  • Drugs PF-06863135 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 10 May 2018 Planned End Date changed from 13 Apr 2022 to 4 May 2022.
    • 10 May 2018 Planned primary completion date changed from 3 Aug 2021 to 24 Aug 2021.
    • 08 May 2018 Planned End Date changed from 29 Nov 2021 to 13 Apr 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top